Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial.
Katherine Hickman, Yasir Tarabichi, Andrew P Dickens, Rachel Pullen, Margee Kerr, Amy Couper, Alexander Evans, James Gatenby, Luis Alves, Cono Ariti, Mona Bafadhel, Victoria Carter, James Chalmers, Rongchang Chen, Graham Devereux, M Bradley Drummond, J Martin Gibson, David M G Halpin, MeiLan Han, Nicola A Hanania, John R Hurst, Alan Kaplan, Konstantinos Kostikas, Barry Make, Douglas Mapel, Jonathan Marshall, Fernando Martinez, Catherine Meldrum, Marije van Melle, Marc Miravitlles, Tamsin Morris, Hana Mullerova, Ruth Murray, Shigeo Muro, Clementine Nordon, Jill Ohar, Wilson Pace, Michael Pollack, Jennnifer K Quint, Anita Sharma, Dave Singh, Mukesh Singh, Frank Trudo, Dennis Williams, Tom Wilkinson, Tonya Winders, David Price
{"title":"Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial.","authors":"Katherine Hickman, Yasir Tarabichi, Andrew P Dickens, Rachel Pullen, Margee Kerr, Amy Couper, Alexander Evans, James Gatenby, Luis Alves, Cono Ariti, Mona Bafadhel, Victoria Carter, James Chalmers, Rongchang Chen, Graham Devereux, M Bradley Drummond, J Martin Gibson, David M G Halpin, MeiLan Han, Nicola A Hanania, John R Hurst, Alan Kaplan, Konstantinos Kostikas, Barry Make, Douglas Mapel, Jonathan Marshall, Fernando Martinez, Catherine Meldrum, Marije van Melle, Marc Miravitlles, Tamsin Morris, Hana Mullerova, Ruth Murray, Shigeo Muro, Clementine Nordon, Jill Ohar, Wilson Pace, Michael Pollack, Jennnifer K Quint, Anita Sharma, Dave Singh, Mukesh Singh, Frank Trudo, Dennis Williams, Tom Wilkinson, Tonya Winders, David Price","doi":"10.15326/jcopdf.2024.0564","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The burden of chronic obstructive pulmonary disease (COPD) is well established, but opportunities for earlier diagnosis and improved management are still missed. Compared to the general COPD population, patients with a history of exacerbations and suboptimal treatment (\"modifiable high-risk\") are at greater risk of future exacerbations and adverse health outcomes. To date there is no systematic approach for identifying and treating this patient group.</p><p><strong>Method: </strong>Two cluster randomized controlled trials (CRTs) in the United Kingdom and United States will assess the impact of a primary care-based quality improvement program (COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care [CONQUEST]), compared to routine care. In each trial, 126 primary care clusters will be randomized 1:1 to intervention or control arms. Three groups of modifiable high-risk patients will be identified using electronic medical records: undiagnosed with potential COPD, newly diagnosed COPD, and already diagnosed COPD. Eligible patients will be aged ≥40 years, have experienced ≥2 moderate/≥1 severe exacerbation(s) in the prior 24 months, including ≥1 in the last 12 months, and not be prescribed inhaled triple therapy. Patients in the undiagnosed group will also be required to have a positive smoking history. Primary trial outcomes will be the annual rate of exacerbations and the annual rate of major adverse cardiac or respiratory events, comparing the quality improvement program against routine care.</p><p><strong>Discussion: </strong>These will be the first CRTs assessing such a comprehensive primary care-based COPD quality improvement program. Intention-to-treat analysis of trial outcomes after 24 months will inform its effectiveness in targeting the identification, assessment, treatment, and follow-up of patients with modifiable high-risk COPD.</p><p><strong>Trial registration: </strong>UK trial: ISRCTN15819828; US trial: NCT05306743.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":" ","pages":"223-239"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15326/jcopdf.2024.0564","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The burden of chronic obstructive pulmonary disease (COPD) is well established, but opportunities for earlier diagnosis and improved management are still missed. Compared to the general COPD population, patients with a history of exacerbations and suboptimal treatment ("modifiable high-risk") are at greater risk of future exacerbations and adverse health outcomes. To date there is no systematic approach for identifying and treating this patient group.
Method: Two cluster randomized controlled trials (CRTs) in the United Kingdom and United States will assess the impact of a primary care-based quality improvement program (COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care [CONQUEST]), compared to routine care. In each trial, 126 primary care clusters will be randomized 1:1 to intervention or control arms. Three groups of modifiable high-risk patients will be identified using electronic medical records: undiagnosed with potential COPD, newly diagnosed COPD, and already diagnosed COPD. Eligible patients will be aged ≥40 years, have experienced ≥2 moderate/≥1 severe exacerbation(s) in the prior 24 months, including ≥1 in the last 12 months, and not be prescribed inhaled triple therapy. Patients in the undiagnosed group will also be required to have a positive smoking history. Primary trial outcomes will be the annual rate of exacerbations and the annual rate of major adverse cardiac or respiratory events, comparing the quality improvement program against routine care.
Discussion: These will be the first CRTs assessing such a comprehensive primary care-based COPD quality improvement program. Intention-to-treat analysis of trial outcomes after 24 months will inform its effectiveness in targeting the identification, assessment, treatment, and follow-up of patients with modifiable high-risk COPD.
Trial registration: UK trial: ISRCTN15819828; US trial: NCT05306743.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
